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Tetrabromobisphenol  A (TBBPA),  a nongenotoxic  ﬂame  retardant,  causes  uterine  tumors  in  female  rats.  A
proposed  mode  of  action  (MoA)  for these  tumors  involves  an increase  in  the  bioavailability  of estradiol  as
a  result  of TBBPA  inhibiting  estrogen  sulfotransferases  (ES),  the  enzymes  responsible  for  inactivating  and
enhancing  the  elimination  of  estradiol.  The  objective  of  this  study  was  to  evaluate  the  effect of  dose  and
repeated  administration  of TBBPA  on  the  level  of TBBPA,  TBBPA-glucuronide  (GA)  and TBBPA-sulfate  (S)
conjugates  in plasma,  liver  and  uterus  of female  Wistar Han  rats  administered  TBBPA  (50,  100,  250,  500
or 1000  mg/kg)  for 28  consecutive  days.  In  accordance  with  this  objective,  TBBPA  sulfation  was  used  as
a surrogate  for  evaluating  the potential  for estradiol  sulfation  to  be  limited  at high  dose  levels  of  TBBPA.
Blood  samples  were  collected  at 4 and  8 h  post-dosing  on  study  day  7, 14,  and  28,  while  liver and  uterus
were  collected  at the same  time  points  following  28 days  of dosing.  Tissue  samples  were  analyzed  for
TBBPA,  TBBPA-GA  and  TBBPA-S  by  LC–MS/MS.  A dose-related  increase  in the concentration  of  all  three
analytes  occurred  in  plasma  (day 7, 14, and  28)  as well  as  liver  and uterus  tissue  (day  28)  at  both  4
and  8 h post  dose.  The  plasma  concentration  of  TBBPA-GA  and  TBBPA-S  was  higher  in  animals  dosed  for
28  days  compared  to  those  dosed  for 7 or 14  days  showing  an  increase  in  systemic  circulation  of  these
conjugates  with  repeated  administration.  The  balance  of  these  conjugates  was  also  different  in  tissues
with TBBPA-S  >  TBBPA-GA  at high  doses  in  the  liver  and  TBBPA-GA  > TBBPA-S  in both  plasma  and  uterus.
In  all  three  tissues  the  ratio  of  TBBPA-S/TBBPA-GA  showed  a  decreasing  trend with  dose,  suggesting
that  at  high  TBBPA  dose  levels  sulfation  of  TBBPA  becomes  limited.  This  effect  was  most  apparent  in
the  liver  and  plasma  at 28 days  of  administration.  Together  these  data  show  that administration  of  high
doses  of  TBBPA  associated  with the  induction  of  uterine  tumors,  results  in  a disruption  in the  balance
of  conjugates  reﬂected  by  a decrease  in  the  TBBPA-S/TBBPA-GA  ratio.  A  limitation  in the  sulfation  of
TBBPA  in  vivo  supports  in  vitro data  deﬁning  TBBPA  as  an  inhibitor  of  ES  activity,  thus providing  further
support  that  the  proposed  MoA occurs  under  conditions  of  high  dose,  chronic  TBBPA  administration  to
Wistar  Han  rats.  Given  that  the uterine  tumors  observed  in  rats  (250–1000  mg/kg-day)  only  occur  at  very
high  doses  that  perturb  homeostatic  control,  it  is  unlikely  such  effects  would  occur  in humans  given that
current  TBBPA  exposure  levels  are  approximately  eight  orders  of  magnitude  lower  than  these  doses  that
are associated  with  exceeding  the capacity  of  conjugation  pathways  in animal  studies.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC∗ Corresponding author at: 1249 Kildaire Farms Road #134, Cary, NC 27511, United
tates.
E-mail address: sborghoff@toxstrategies.com (S.J. Borghoff).
ttp://dx.doi.org/10.1016/j.toxrep.2016.01.007
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Tetrabromobisphenol A (TBBPA) is the most widely produced
brominated ﬂame retardant, primarily because of its effectiveness
and low hazard proﬁle (http://www.bsef.com). It is used in epoxy,
polycarbonate and phenolic resins in circuit boards, as well as in
acrylonitrile–butadiene–styrene (ABS). Examples of products con-
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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aining TBBPA include printed circuit boards, communications and
lectronics equipment, appliances, transportation devices, sports
nd recreation equipment, automotive parts, pipes and ﬁttings [2].
umans can be exposed to TBBPA during manufacturing and pro-
uction, via use of TBBPA-containing products, and via recycling of
BBPA-containing products. TBBPA has been detected in the ppb
ange in human serum in cases of exposure in occupational and
on-occupational settings, as well as in breast milk, demonstrat-
ng that TBBPA is in fact absorbed in exposed human populations
19,34,32,33].
The acute oral toxicity of TBBPA in rats is low (LD50 > 5 g/kg) [18],
ith little toxicity identiﬁed overall in a number of robust stan-
ard 28- and 90-day toxicology studies [8,28,38,29]. In a recent
ancer bioassay conducted by the National Toxicology Program
NTP), TBBPA was administered to Wistar Han rats at dose lev-
ls of 250, 500, and 1000 mg/kg for 2 years. The NTP reported
n increased incidence of uterine epithelial tumors in female rats
combined adenoma, adenocarcinoma, or malignant mixed Mul-
erian tumor) at the mid- and high dose levels of 500 mg/kg-day
32%) and 1000 mg/kg-day (38%), when compared to the vehicle
ontrol group (12%) [28]. Given that TBBPA has been shown not to
e mutagenic or genotoxic [15,8], several investigators have pro-
osed a mode of action (MoA) for uterine tumors that involves
ndocrine mediated events that would result in a disruption of
strogenic activity [6,26]. A review of both the published literature
nd high throughput screening (HTS) data (http://actor.epa.gov/
dsp21/) has shown that TBBPA does not directly interact with the
strogen receptor (ER) [42]. Based on the lack of ability of TBBPA to
e an ER agonist, the focus of this current investigation has been on
he ability of TBBPA to directly disrupt the metabolism of estrogen.
To date, toxicokinetic data on TBBPA are limited to relatively
raditional kinetic studies. Existing data reﬂect administration of
arying dose levels of TBBPA for different durations in order to
haracterize TBBPA’s major metabolites in multiple strains of rats
nd humans [12,25,31,20,24]. Overall, TBBPA is rapidly absorbed
nd efﬁciently metabolized by glucuronyltransferase and sulfo-
ranferase enzymes in the liver. The major route of elimination of
dministered TBBPA is in feces, with minor elimination in urine
esulting in low bioavailability [12,25,24]. Together the data from
hese studies support the conclusion that TBBPA is cleared via bile
or fecal elimination with the two major metabolites identiﬁed as
 TBBPA-sulfate and TBBPA-glucuronide conjugate.
Similar to TBBPA, estrogen and its metabolites are conjugated
o both sulfate and glucuronic acid, with sulfation serving as the
ain pathway for the inactivation of estrogen [43]. Kester et al.
21] reported that TBBPA inhibits estrogen sulfotransferase (ES)
n vitro with IC50 values ranging from 12 to 33 nM.  Another study
onducted by Hamers et al. [13] conﬁrmed that TBBPA acts as a
otent inhibitor of ES in vitro (IC50 = 16 nM), with it being approx-
mately 13 times more potent than pentachlorophenol (PCP), a
nown inhibitor of sulfotransferase. A QSAR study evaluated bind-
ng to ES and found that TBBPA fulﬁlled the chemical structure
riteria that would predict potent inhibition of ES [14]. A more
ecent evaluation of the crystal structure of ES involving computa-
ion modeling found that TBBPA binds to the same site as estradiol
10]. Taken together, these studies provide evidence to support the
ypothesis that TBBPA inhibits ES, and more speciﬁcally the iso-
orms SULT1E1 and SULT1A1. When these data are considered, and
etabolic pathways for TBBPA and estrogen compared (Fig. 1), it
ppears that TBBPA could compete in vivo with the same enzyme
ystems as estrogens. However, currently there are no data avail-
ble to characterize such a relationship in vivo—and, importantly, to
haracterize the doses at which ES inhibition may  occur and affect
he sulfation of estrogens. These data are critical for determining
he feasibility for TBBPA to inﬂuence estrogenic potential through
 disruption of its metabolism. Several studies [6,26] proposed thateports 3 (2016) 190–201 191
the TBBPA-inhibition of ES, a key enzyme in the inactivation and
elimination of estrogens, would potentially result in an increased
bioavailability of estrogens, which, in both humans and rats, is asso-
ciated with endometrial tumors [16].
Kinetic data are not yet available to determine if the adminis-
tration of TBBPA at dose levels used in the NTP study that were
associated with uterine tumors in rats, inhibits ES in vivo, and
subsequently, if such an inhibition could result in an increased
bioavailability of “unconjugated” estradiol in the uterus (an estro-
gen responsive tissue). Based on the challenges associated with
directly measuring estrogens and its metabolites in tissues (e.g.,
assay sensitivity, speciﬁcity, and variability), the objective of this
study was to determine if conjugation of TBBPA to sulfate would
be limited at dose levels associated with the development of pre-
neoplastic and neoplastic changes in the uterus of rats following
chronic administration of TBBPA. TBBPA sulfation can be used as
a surrogate for indirectly measuring the potential disruption in
estradiol conjugation since both are metabolized through the same
enzyme systems. Investigating the dose level at which the sulfa-
tion of TBBPA exceeds its capacity would provide further support
that the sulfation of estradiol in vivo would be impacted following
repeated high dose levels of TBBPA.
2. Materials and methods
2.1. Chemicals
Tetrabromobisphenol A (TBBPA) [CAS No. 79-94-7] was
obtained from Albemarle Corporation (Baton Rouge, LA) with a
purity of 98.83%. Corn oil [CAS no. 8001-30-7], used as the vehicle,
was obtained from MP  Biomedical, LLC (Solon, OH). All reagents
used for LC–MS/MS analysis were HPLC grade. 13C12-TBBPA was
purchased from Cambridge Isotope Laboratories and control rat
plasma was purchased from Innovation Research Inc.
2.2. TBBPA dose formulation
TBBPA dose formulations were prepared in corn oil at concentra-
tions of 0, 10, 20, 50, 100, and 200 mg/mL  to administer dose levels
of 0, 50, 250, 500, and 1000 mg  TBBPA/kg body weight, respectively,
at a volume of 5 mL/kg. TBBPA dose formulations were reported
to be stable in corn oil at room temperature for up to 40 days
[28]. As such, dose formulations were prepared once every 2 weeks
(2×)  during this 28-day study. Dose concentration and homogene-
ity were conﬁrmed by sampling the top, middle and bottom of
each formulation and analyzing by HPLC-UV (285 nm) using a Shi-
seido Capcell Pak C18 column, 3 × 100 mm,  3 m with a ﬂow of
0.6 mL/min. Brieﬂy, the HPLC method consisted of a mobile phase of
0.1 mL  of triﬂuoroacetic acid (TFA) in deinonized water (A) and (B)
0.1 mL  of TFA in acetonitrile. The gradient was 0 to 40% B over 4 min
with a linear increase to 100% B up to 6 min. Approximate reten-
tion time for TBBPA was 5.6 min. Concentration and homogeneity
results were acceptable if the mean concentration was within 15%
of the target and the coefﬁcient of variation in the homogeneity
was less than 15%.
2.3. Animal model
Female Wistar (CRL:W(Han)) rats were obtained from Charles
River Laboratory International, Inc (Kingston, NY) at approximately
9 weeks of age and supplied with NTP-2000 wafer diet (Zeigler
Bros., Gardners, PA) and reverse-osmosis-treated tap water (City of
Durham, NC) ad libitum.  Animals were acclimated for 8 days prior
to the initiation of the study and housed 3 per cage in polycar-
bonate cages with absorbent heat-treated hardwood bedding. The
temperature and humidity of the animal rooms were held between
192 S.J. Borghoff et al. / Toxicology Reports 3 (2016) 190–201
Fig. 1. Schematic to illustrate the competition of TBBPA with estradiol for sulfation and potentially glucuronidation in vivo. SULT1E1 and SULT1A1 are estrogen sulfotrans-
ferases with 3′-phosphoadenosine 5′-phosphosulfate (PAPS) being the cofactor that donates sulfate. Members of the glucuronyltransferase family, UGT1 have preferential
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ts  metabolites using uridine diphosphate glucuronic acid (UDPGA) to donate glucu
ompounds, polycyclic aromatics and compounds with bulky side chain ring substi
3.4–25.1◦C and 41–64.9%, respectively, with a 12/12 h light/dark
ycle. All animal procedures were in compliance with the Animal
elfare Act Regulations, 9CRF 1–4 with animals being handled and
reated according to the Guide for the Care and Use of Laboratory
nimals [17].
.4. Study design
Strain of rats, animal vendor, diet and dose formulation (corn oil
s vehicle) were identical to the speciﬁcations used in the TBBPA
hronic NTP study [28]. Female Wistar Han rats (10 weeks of age)
ere allocated to one of six designated dose groups using a pro-
edure that stratiﬁes animals across groups by body weight such
hat the mean body weight of each group was not statistically
ifferent from any other group. Within each dose group animals
ere designated for tissue collection at either 4 or 8-h post dos-
ng (n = 6 per group). Animals were administered corn oil (vehicle
ontrol- 0 mg/kg TBBPA) or one of the ﬁve dose levels of TBBPA
50, 100, 250, 500, and 1000 mg/kg) by oral gavage daily for 28
onsecutive days. Body weight measurements and clinical obser-
ations were performed within 2 days upon animal arrival, prior
o dose group allocation and daily prior to dose administration.
lood was collected in EDTA containing tubes from animals via the
etro-orbital plexus (under isoﬂurane anesthesia) 4 and 8 h follow-
ng dose administration on study days 7 and 14 and processed to
lasma. At study termination on day 28, blood was collected (pro-
essed to plasma) under isoﬂurane anesthesia by cardiac puncture
t 4 and 8 h following the ﬁnal dose and the liver and uterus col-
ected, weight recorded and tissue specimens were ﬂash frozen in
iquid nitrogen prior to storing at/or below −70 ◦C. Plasma was  pre-
ared by centrifugation of blood at 10,000 × g for 5 min  at 4 ◦C and
tored at or below −70 ◦C.
.5. Liquid chromatography/mass spectrometry (LC–MS/MS)
In preparation for analysis, liver and uterine tissues were
hawed on ice and homogenized in deionized water at a ratio of
 mL  per 1 g of tissue using a PowerGen 125 (∼15,000–20,000 rpm)
or 30 s pulses to minimize heat. For uterine tissue homogenates,
n additional 1 mL  of ice-cold deionized water was  added and fur-
her homogenized using a Retsch Mixer Mill with four steel beads
er sample for 5 min  at 30 cps. Homogenates were stored frozen at
r below –70 ◦C until analyzed.. UGT1A1 is identiﬁed as the isoform involved with the conjugation of estradiol and
 acid. UGT1A7 has broad speciﬁcity and glucuronidates both planar and nonplanar
s [40,27].
Plasma and liver homogenate (20 L) samples were fortiﬁed
with the internal standard 13C12-TBBPA in acetonitrile. Precipitated
proteins were removed by centrifugation. Approximately 200 mg
of uterine tissue homogenate was extracted (2x) with methyl tert-
butyl ether (MTBE). MTBE layers were combined into a single clean
tube, evaporated to dryness under nitrogen and samples dissolved
in 50% methanol containing the internal standard 13C12-TBBPA.
TBBPA, TBBPA-GA and TBBPA-S were quantitated by LC-MS/MS
using electrospray ionization. Samples were separated on a Cap-
cell Pak C18 HPLC column (3 × 100 mm;  3 m; Shiseido, Japan)
using an Agilent 1100 autosampler and an Agilent 1100HPLC pump.
Separation was performed by gradient elution with 8 mM  ammo-
nium acetate (solvent A) and acetonitrile/8 mM ammonium acetate
(solvent B) using the following conditions: 90% A, 10% B, linear
increase to 100% B within 3 min, isocratic for 2 min  at a ﬂow rate of
500 L/min. The HPLC system was  directly coupled to a triple-stage
quadrupole mass spectrometer (API 4000, Applied Biosystems)
using a 3:1 split. Analytes were detected in the negative-ion mode
at a vaporizer temperature of 450 ◦C and a TurboIon Spray voltage
of 4.5 kV. Analysis was performed using multiple reaction monitor-
ing (MRM)  mode using two  individual transitions for each analyte.
The transitions were 542.700/445.800 m/z, 622.700/542.700 m/z,
and 718.700/113.00 m/z for TBBPA, TBBPA-S and TBBPA-GA, respec-
tively similar to those previously reported by [31]. Fig. 2 provides
a representative extracted ion chromatograph for TBBPA, TBBPA-
S and TBBPA-GA in plasma. Tentative assignments for conjugates
other than TBBPA-S and TBBPA-G are provided in Fig. 2. These were
based on the previous evidence provided by Schauer et al. [31] and
supported by their detection in the respective MRM  channels for
TBBPA-S or TBBPA-G and relative chromatographic retention.
2.6. Quantitation of TBBPA, TBBPA-GA, and TBBPA-S in tissues
Quantitation of TBBPA was based on the responses of the
internal standard and on calibration curves obtained by forti-
fying plasma and liver samples from control rats with TBBPA
over the concentration range of ∼2–40,000 ng/mL. Based on lim-
itation in sufﬁcient uterine tissue to prepare calibration curves,
recovery of analyte from the uterus was  determined by spiking
TBBPA at low, mid- and high levels of the solvent calibration curve
(0.2–4,000 ng/mL) to determine the extraction efﬁciency (EE). The
EE averaged 30% and was used to calculate analyte concentration.
S.J. Borghoff et al. / Toxicology Reports 3 (2016) 190–201 193
F BBPA
u conju
d
c
m
w
1
a
c
r
o
r
c
p
c
t
C
t
B
2
q
t
f
a
o
2
b
l
v
t
w
g
(ig. 2. Representative extracted ion chromatogram (EIC) for TBBPA, TBBPA-S and T
terus. The x-axis is time (min) and the y-axis is intensity (CPS). * denotes putative 
iconjugate) as described in Section 2.5.
Since TBBPA-GA and TBBPA-S reference standards were not
ommercially available, the relative response ratios were deter-
ined for these TBBPA conjugates against TBBPA. TBBPA conjugates
ere extracted from feces collected from rats administered
000 mg/kg TBBPA as previously described by [31]. The extract was
nalyzed by HPLC-UV and molar ratio of TBBPA to conjugate cal-
ulated by determining the molar ratio by HPLC-UV and ionization
esponse using the LC/MS MRM  method described above. The ratio
f the responses of conjugates to TBBPA was then used as a cor-
ection factor in calculating levels of conjugates from the TBBPA
alibration curves.
The concentration of TBBPA was calculated by direct com-
arison to the calibration curve, and the concentration of each
onjugate was  calculated by applying the corrected molar ratio
o the response ratio of the conjugate and TBBPA in the sample.
alibration curves were calculated from eight to twelve calibra-
ion concentrations using Analyst, 1.5 processing software (Applied
iosystems, Waltham, MA). The LOD for TBBPA ranged from 0.02 to
 ng/mL depending on analyte and matrix with the lower limit of
uantitation (LLOQ), determined as the lowest point on the calibra-
ion curve that achieved ± 15% back-calculated recovery, ranging
rom ∼0.2 ng/mL (uterus) to 4.1 ng/mL (plasma and liver) for TBBPA
nd from 0.1 (uterus) to 2.73 ng/mL (plasma and liver) for TBBPA-S
r TBBPA-GA.
.7. Statistical analysis
Descriptive statistics (mean and standard deviation) of initial
ody weight, ﬁnal body weight, body weight gain, and absolute
iver and uterus weights were calculated and analyzed using SAS
ersion 9.2 (SAS Institute, Cary, NC). Homogeneity of variance on
hese weights was analyzed using Levene’s test. Homogenous data
ere analyzed using a one-way analysis of variance and treated
roups were compared to the control group using Dunnett’s t-test
two-tailed). Descriptive statistics (mean and standard deviation)-GA conjugates quantitated in plasma, with similar scans observed in the liver and
gates, TBBPA-GA/S (diconjugate of glucuronide and sulfate) and TBBPA-S/S (sulfate
of TBBPA, TBBPA-GA, and TBBPA-S tissues levels were calculated
and analyzed using GraphPad Prism® (GraphPad Software, Inc., San
Diego, CA). If the analyte concentrations were below the LLOQ the
values were set to LLOQ/2 to evaluate dose-related trends. Ana-
lyte concentrations in each group were evaluated for outliers prior
to statistical analysis using a two-sided Grubb’s test. To assess
dose-related changes of analytes, a trend test was conducted and
statistical signiﬁcance reported if p < 0.05. To compare levels of con-
jugates at speciﬁc dose groups and time points, Students t-test was
performed. Statistically-signiﬁcance was reported when p < 0.05.
3. Results
3.1. Dose formulation analysis
The two  highest dose formulation concentrations (100 and
200 mg/mL) were suspensions. Homogeneity was  evaluated in all
dose formulations as described in the method sections with all for-
mulations administered to rats found to be within 15% of the target
concentration with the coefﬁcient of variation less than 15% for
homogeneity. The actual concentrations prepared over the course
of the study are listed in Table 1 of the supplemental materials.
3.2. Clinical Observations
There were no abnormal observations related to the adminis-
tration of TBBPA during the course of the study. One animal in the
500 mg/kg group was found dead following dose administration on
study day 21 due to suspected dosing error. No other instances of
mortality or morbundity were observed.3.3. Terminal body, liver and uterine weights
Body weight gain did not change with dose of TBBPA (data not
shown), nor was there any signiﬁcant difference in the ﬁnal ter-
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Fig. 3. Liver; the concentrations (ng/gram of tissue) of A TBBPA, B TBBPA-GA, and C TBBPA-S with dose at 4- and 8-h following dosing on day 28. Each bar represents the
mean  ± SD (n = 4–6 per group). (*) indicates a signiﬁcant dose-related increasing trend (p < 0.01). (ˆ) indicates a signiﬁcant decrease in the analyte at each dose level at 8 h
compared to the 4-h time point (p < 0.05).
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aig. 4. Liver; the concentrations (ng/gram of tissue) of TBBPA-GA and TBBPA-S at A
roup). (ˆ) indicates a signiﬁcantly higher concentration of TBBPA-S compared to TB
inal body weight on day 28 at any TBBPA dose level compared
o the vehicle control group (Table 2 of the supplemental materi-
ls). There were no signiﬁcant changes noted in the absolute liver
r uterine weights at any dose level of TBBPA compared to vehi-
le control rats, nor were there any dose-related trends in liver or
terine weights at either 4- or 8-h post dose on day 28 (Table 2 of
he Supplemental materials).
.4. Liver concentrations of TBBPA, TBBPA-GA and TBBPA-S
The concentrations of TBBPA, TBBPA-GA and TBBPA-S measured
n liver tissue collected from rats administered TBBPA for 28 con-
ecutive days increased with dose of TBBPA (trend test; p < 0.01)
t 4- and 8-h following the last dose (Fig. 3). The concentration
f TBBPA at 8-h was signiﬁcantly lower than at 4-h at the two
ighest dose levels (t-test, p < 0.05). The concentration of TBBPA-
 was signiﬁcantly higher (t-test, p < 0.05) than the concentration
f TBBPA-GA at all dose levels (Fig. 4), demonstrating that sulfation
s the major pathway for conjugation of TBBPA in liver. To evaluate
he balance of these conjugates with dose and time, the ratio of the
onjugates to the parent compound (TBBPA), as well as with each
ther, were evaluated at 4- and 8-h following the last dose on day
8. The GA/TBBPA ratio increased with dose (trend test, p < 0.05)
Fig. 5A and D) with no change in the S/TBBPA ratio (Fig. 5B and E)
t both the 4- and 8-h time points. The proportion of TBBPA sul- B 8 h= following dosing on day 28. Each bar represents the mean ± SD (n = 4–6 per
GA at each dose level (t-test, p < 0.05).
fated vs. glucuronidated, as reﬂected in S/GA ratio, decreased with
dose at both the 4- and 8-h time points (trend test, p < 0.05) (Fig. 5C
and F), suggesting that the sulfate pathway becomes limited with
administration of high doses levels of TBBPA.
3.5. Plasma Concentrations of TBBPA, TBBPA-GA and TBBPA-S
The plasma concentration of TBBPA in rats administered TBBPA
for 7, 14, and 28 days increased with TBBPA dose level (trend test,
p < 0.01) at both 4- and 8-h following the last dose on each respec-
tive day, with lower levels measured at 8 h compared to the 4-h
time point at the higher dose levels (t-test, p < 0.05) (Fig. 6). Simi-
lar to the parent TBBPA, the conjugates increased with TBBPA dose
level (trend test, p < 0.01) at both 4- (Fig. 7) and 8-h (data not shown)
following the last dose on each respective day. TBBPA-GA plasma
levels were higher compared to levels of TBBPA-S at dose levels
>250 mg/kg (t-test, p < 0.05) (Fig. 7) at 4-h post dose. TBBPA-GA
and TBBPA-S plasma levels were signiﬁcantly higher following 28-
days of dosing compared to either 7 or 14 days at dose levels above
50 mg/kg (p < 0.05) (Fig. 8), suggesting increased conjugation with
repeated administration of TBBPA. Similar to what was observed in
the liver, the GA/TBBPA ratio evaluated in plasma increased with
dose (trend test, p < 0.01) with no change in the S/TBBPA ratio at
either 4- or 8-h following dosing on day 28 (Fig. 9). Since the lev-
els of conjugates were at/or below the LLOQ in rats administered
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ndicates a signiﬁcant dose-related increasing trend (p < 0.01). (ˆ) indicates a signiﬁ
oint  (p < 0.05).
0 mg/kg TBBPA, these trends were evaluated at the dose level of
00 mg/kg and above. The proportion of TBBPA sulfated vs. glu-
uronidated decreased with dose (trend test, p < 0.01 at 4 h and
 < 0.05 at 8 h) as reﬂected in the S/GA ratio, again similar to the
hanges observed in the liver.
.6. Uterine concentrations of TBBPA, TBBPA-GA and TBBPA-S
Similar to liver and plasma, the concentration of TBBPA and con-
ugates in the uterus increased with dose of TBBPA at both 4- and
-h following dosing on day 28 (trend test, p < 0.01) (Fig. 10). Again,
igher levels of TBBPA were measured at 4-h compared to 8-h post
ose at dose levels of 250 mg/kg and above (t-test, p < 0.05). Thed C 28-days of dosing. Each bar represents the mean ± SD (n = 4–6 per group). (*)
ecrease in TBBPA concentration at each dose level at 8-h compared to the 4-h time
concentration of TBBPA-GA was  higher at 4-h compared to 8-h but
only statistically signiﬁcant following administration of the high-
est dose level of 1000 mg/kg dose (Fig. 10). Similar to plasma, the
concentrations of TBBPA-GA in the uterus were higher compared
to TBBPA-S at both 4- and 8-h post dosing, however, statistical
signiﬁcant in this tissue was only detected at the highest dose of
1000 mg/kg (t-test, p ≤ 0.05) (Fig. 11). The dose-related trends in the
ratio of conjugates to parent and each other that were observed in
liver and plasma were also observed in the uterus, however due to
the higher variability and lower concentration of these analytes in
this tissue statistical signiﬁcance was only observed for in the S/GA
ratio at the 4-h time point (decreasing trend) and in the GA/TBBPA
196 S.J. Borghoff et al. / Toxicology Reports 3 (2016) 190–201
50 10
0
25
0
50
0
10
00
1
10
100
1000
1000 0
Dose (mg/kg)
ng
/m
L
A. Day 7; 4 hours 
50 10
0
25
0
50
0
10
00
1
10
100
1000
10000
Dose (mg/kg)
ng
/m
L
B. Day 14; 4 hours 
TBBPA-GA
TBBPA-S
50 10
0
25
0
50
0
10
00
1
10
100
1000
10000
100000
Dose (mg/kg)
ng
/m
L
C. Day 28; 4 hours
*
*
*
^
^ ^
^ ^ ^
**
*
Fig. 7. Plasma; The concentration of TBBPA-S and TBBPA-GA at 4 h following 7, 14, and 28 days of consecutive dosing. Each bar represents the mean ± SD (n = 4–6 per
group). (*) indicates a signiﬁcant dose-related increasing trend in TBBPA-GA and TBBPA-S at A 7, B 14, and C 28-days of dosing (p < 0.01). (ˆ) indicates a signiﬁcantly higher
concentration of TBBPA-GA compared to TBBPA-S at each dose level (p < 0.05).
50 10
0
25
0
50
0
10
00
1
10
100
1000
10000
1000 00
Dose (mg/kg)
ng
/m
L
A. TBBPA-GA
50 10
0
25
0
50
0
10
00
1
10
100
1000
10000
Dose (mg/kg)
ng
/m
L
B. TBB PA-S
Day 7
Day 14
Day 28
^
^
^ ^
^
^ ^
^
F ing on
i 4 (p < 0
r
(
3
s
a
t
a
e
d
l
t
a
s
d
4
l
i
o
Fig. 8. The concentration of A TBBPA-GA and B TBBPA-S in plasma 4 h following dos
ndicates a higher concentration of conjugate at day 28 compared to day 7 or day 1
atio (increasing trend) at the 8-h time point (trend test, p < 0.05)
Fig. 12).
.7. Comparison of analytes in all three tissues
The overall changes in TBBPA, TBBPA-GA and TBBPA-S, mea-
ured in all three tissues at 4 h following dosing on study day 28,
re shown in Fig. 13. These dose-related changes in the concentra-
ion of all three analytes suggest saturation of conjugation of TBBPA
t doses approximately ≥250 mg/kg in liver, plasma, and uterus. To
valuate the liver or uterus/plasma ratio for all three analytes, the
ose-related trends were evaluated starting at the 100 mg/kg dose
evel. The 100 mg/kg dose level was chosen as the cutoff because
he levels of conjugates in the plasma samples at 50 mg/kg were
t/or below the LLOQ. Fig. 14 shows that overall these ratios are the
ame with dose except for the TBBPA-S liver/plasma ratio which
ecreases with dose of TBBPA (trend test, p < 0.5).
. Discussion
In this study we evaluated the effect of repeated dosing, dose
evel, and time post dosing on the concentrations of TBBPA and
ts glucuronide and sulfate conjugates in liver, plasma and uterus
f female Wistar Han rats administered TBBPA for up to 28 days.
ollowing 28 days of dosing at levels up to 1000 mg  TBBPA/kg, study day 7, 14, and 28. Each bar represents the mean ± SD (n = 4–6 per group). (ˆ)
.05).
there were dose-related increases in the concentration of TBBPA
and its major conjugates, TBBPA-GA and TBBPA-S in liver, plasma,
and uterine tissue. The concentration of TBBPA-S was higher in liver
compared to TBBPA-GA, while an inverse relationship was  observed
in the plasma and uterus at high dose levels. Overall, the ratio of the
TBBPA-S to TBBPA-GA in all three tissues decreased with increas-
ing dose level of TBBPA, suggesting the sulfation pathway becomes
limited with increased dose of TBBPA. When considering the pub-
lished in vitro data, which demonstrate both binding and inhibition
of ES by TBBPA [21,13], the data from this current in vivo study pro-
vides an additional line of evidence supporting the hypothesis that
high doses of TBBPA limit estradiol sulfation serving as the molec-
ular initiating event in the MoA  associated with development of
uterine tumors in Wistar Han rats.
The data in this study are consistent with other kinetic investi-
gations of TBBPA [25,31,20,24]. Most notably, Knudsen et al. [24]
reported that the elimination pathways of TBBPA in female Wis-
tar Han rats become saturated following even a single oral dose
of 1000 mg/kg, which resulted in a slower excretion. The authors
attributed this delay to a potential competition for metabolism with
endogenous substrates in extrahepatic tissues, which these authors
noted could result in endocrine disruption. Although [24] did not
observe a delay in elimination at lower doses (25 or 250 mg/kg),
kinetics were only evaluated after a single dose. The data presented
in the current study build on these ﬁndings, demonstrating that
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fter 28 days of administration, sulfation was limited at doses of
250 mg/kg-day and above.
As noted by Kester et al. [21] the competitive or noncompetitive
nhibition of estradiol sulfation may  be explained by a chemical’s
referential afﬁnity for the active or the allosteric site, respec-
ively. Although not determined speciﬁcally for TBBPA, Kester
t al. [21] showed that 3,3,5,5′-tetrachlorobisphenol A (not TBBPA)
nhibits SULT1E1 by a noncompetitive mechanism. Gosavi et al. [10]
emonstrated in a crystallization experiment that in the presence
f both estradiol and TBBPA, binding of estradiol to SULT1E1 did
ot permit the binding of TBBPA at another position. The observedA-S with dose at 4- and 8-h following dosing on day 28. Each bar represents the
< 0.01). (ˆ) indicates a signiﬁcantly higher concentration of analyte at 4 h compared
electron density was consistent with both molecules completing
for binding at the same catalytic site. The potential inhibition of
sulfation may  also be inﬂuenced by the ability of TBBPA to inhibit
the binding of the cofactor PAPS to SULT1E1. Although there is no
direct evidence in the literature concerning such, Gosavi et al. [10]
described that the speciﬁc inhibition of TBBPA may  be a result of
high-afﬁnity binding to the SULT1E1-PAP postcatalytic complex.
An understanding of the mechanism by which TBBPA inhibits sul-
fotransferase would be useful to understand the potential tissue
and species speciﬁcity of the overall limitation in this metabolic
pathway in vivo.
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fig. 12. Uterus; ratio of TBBPA-GA (GA)/TBBPA (A and D), TBBPA-S (S)/TBBPA (B an
ach  bar represents the mean ± SD (n = 4–6 per group). (*) indicates a signiﬁcant do
Evaluation of changes in the concentration of TBBPA and
oth the TBBPA glucuronide and sulfate conjugates in liver was
mportant given that it is the key organ system following oral
dministration (ﬁrst pass effect) having a major role in the
etabolism of TBBPA. TBBPA was also metabolized to diconjugates
hat were only putatively identiﬁed, but not quantitated in this
tudy or in a study described by Schauer et al. [31] since only the
onoconjugates were isolated and extracted from the feces of rats
dministered TBBPA. Measuring the level of TBBPA and its conju-
ates in plasma provided an overall assessment of the systemic
xposure to TBBPA and its conjugates, that appears to be the the
ource of target tissue (e.g., uterus) exposure.
It is also critical to note that the liver is largely responsible
or the synthesis of estrogens and is involved in its subsequentand S/GA(C and F) with dose at 4 and 8 h following 28 days of consecutive dosing.
ated increasing (D) or decreasing (C) trend (p < 0.05).
metabolism. Estrogens can undergo both phase I and phase II
metabolism with conjugation by both sulfotransferases and glu-
curonosyltransferases. Conjugation of estrogen in turn increases
its elimination and decreases the ability of estrogens to bind to the
estrogen receptor [30]. Though levels of estradiol and its conjugate
were not obtained in this study, these data demonstrated, using
TBBPA conjugation patterns as a surrogate, that sulfation is limited
in the liver as well as in the target tissue (uterus) following admin-
istration of high dose levels of TBBPA. These ﬁndings are critical
for characterizing the ability of TBBPA at high dose levels to limit
the sulfation pathway in vivo and subsequently limiting estrogen
sulfation due to its ability to inhibit these enzymes and poten-
tially overwhelm the capacity of this pathway. Factors that would
play a role in the regulation of local estrogen levels in the uterus,
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roup). (*) indicates a signiﬁcant dose-related decreasing trend (p < 0.05).
he target tissue of interest, will ultimately depend on the poten-
ial for TBBPA to inhibit ES and glucuronosyltransferases in vivo,
long with the reversal of these conjugates by local tissue levels
f sulfatases or glucuronidases. In the case of sulfation, since this
nzyme pathway is a high-afﬁnity, low-capacity process, the bind-
ng of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) (the cofactor
hat donates sulfate to the enzyme outlined in Fig. 1), along with its
vailability, is also critical in determining the level of sulfate con-uterus tissue 4 h post dosing on day 28. Each symbol is the mean ± SD (n = 4–6 per
jugate formed, whether it is with TBBPA or estradiol. Klaassen and
Boles [22] demonstrated that in rats, the limited sulfation capac-
ity is due to availability of sulfate, and that there are differences in
sulfation capacity by tissue. These factors (e.g., sulfotransferase and
sulfatase activity and PAPS availability) together determine the lev-
els of sulfate conjugates formed in tissues, whether the substrate
is TBBPA or estradiol.
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Based on the proposed MoA  that TBBPA induces rat uterine
umors through its ability to inhibit ES and increase the bioavail-
bility of estrogens, it is important to compare the metabolism of
strogens in both humans and rats. Wang and James [39] pro-
ide information on the tissue distribution of sulfotransferases
n humans, with identiﬁcation of the major substrates including
henols, catecholamines, thyroid hormone, estrogens and hydrox-
steroids. The endometrium is an estrogen responsive tissue in
oth rats and humans and is known to express ES in human tis-
ue [37]. The ES isoform, SULT1E1, has been shown to exhibit a
articularly high afﬁnity for estradiol and is primarily responsible
or estrogen metabolism in humans [9,4,43]. However, much less
nformation is available in other species. With respect to estrogen
etabolism, one study found that estradiol glucuronidation was
ore active in the uterus of Wistar Han rats compared to estradiol
ulfation suggesting that the rat uterus is not a source of sulfotrans-
erase enzymes [1]; however these animals were ovariectomized,
nd activity of SULT1E1 was not speciﬁcally evaluated. Dunn and
laassen [5] did report the lack of detection of sulfotransferase
RNA in the rat uterus. As such, homeostatic characterization of
strogen metabolism in the Wistar Han rat uterus remains a data
ap. This is particularly notable given that this strain of rats appears
o have a higher incidence of uterine tumors compared to other
trains reviewed [23,42]. The data collected in this current study
uggest that the concentration of TBBPA and conjugates measured
n the uterus are most likely due to its translocation from plasma
ince the balance of conjugates was the same in the plasma and
terus. It is of interest to note that at 4–8 h following adminis-
ration of 50 mg/kg TBBPA (a dose that is 10× lower than a dose
ssociated with uterine tumors), the mean TBBPA plasma level was
pproximately 1478 nM,  an estimated 45–123× higher than the
C50 value associated with the inhibition of estrogen sulfotrans-
erase by TBBPA reported in vitro (12–33 nM)  [21] demonstrating
hat the concentration of TBBPA in the plasma is well above the
oncentration shown to inhibit ES activity in vitro.
Perhaps the most critical ﬁnding from this current study is the
bservation that metabolism of TBBPA at high doses appears to be
onlinear. It is well established that one should proceed with cau-
ion when extrapolating ﬁndings from animals to humans when
he adverse effects only occur in animals at high doses and the evi-
ence suggest that such ﬁndings are the result of perturbed normal
hysiological functions and protective mechanisms to humans [35].
he adverse effect of concern in the NTP study, uterine tumors,
nly occurred following chronic administration of TBBPA at very
igh doses (500 and 1000 mg/kg-day). As suggested by Wikoff
t al. [42], several lines of evidence support that these tumors
ccur via an initial event involving inhibition of ES (e.g., perturbed
ormal physiological functions). As such, there are clearly chal-
enges with respect to characterizing and extrapolating the uterine
umors observed in rats to potential effects to humans, as even
he lowest dose tested by the NTP was orders of magnitude higher
han estimates of human exposure reported in the scientiﬁc lit-
rature [8,15,7,3,41]. In the case of TBBPA, dose levels of TBBPA
n the NTP bioassay ranged from 250 to 1000 mg/kg-day, whereas
uman exposure has been estimated by multiple entities to be
0.00008 mg/kg-day [8,15,7,41].
Data from the current study demonstrate that the sulfation
athway at repeated TBBPA dose levels of ∼250 mg/kg-day and
reater becomes limited in its capacity, an observation that is
onsistent with the incidence of atypical endometrial hyperplasia
eported in the National Toxicology Program (NTP) study (e.g., 4,
6, 22, and 26% at 0, 250, 500, and 1000 mg/kg-day, respectively)
NTP, 2014). The statistically signiﬁcant increase in uterine tumors
combined) however, observed in the 500 and 1000 mg/kg-day
ose groups, highlights that it is most likely the combined inﬂu-
nce of high dose of TBBPA at levels that inhibit ES and prolongedeports 3 (2016) 190–201
(chronic) exposure to unconjugated estradiol together are critical
for the development of uterine tumors. Additionally, the data from
this current study demonstrates the need for lower-dose toxicoki-
netic studies that evaluate the toxicokinetic behavior of TBBPA after
longer exposures, a data gap recently identiﬁed by the [36].
In conclusion, though there are a number of studies in the lit-
erature that have evaluated the toxicokinetics of TBBPA in rats
and humans, none speciﬁcally focus on the inﬂuence of dose- and
repeated administration of TBBPA on selected tissue levels of TBBPA
and its conjugates. This approach provided the opportunity to eval-
uate the sulfation of TBBPA as a surrogate for understanding the
potential disruption in estradiol sulfation. Findings from this cur-
rent study demonstrate that metabolic capacities are altered in
female Wistar Han rats following repeated, high dose administra-
tion of TBBPA; speciﬁcally in key enzyme pathways involved in the
metabolism of both TBBPA and estradiol that exceed its capacity
at high TBBPA doses levels (i.e., at doses that result in perturba-
tion of homestatic conditions). Therefore, given that the uterine
tumors observed in rats in the NTP study (250–1000 mg/kg-day)
only occur at very high doses that perturb homeostatic control, it
is unlikely such effects would occur in humans given that current
TBBPA exposure levels are approximately eight orders of magni-
tude (or more) lower than these doses that are associated with
exceeding the capacity of key enzyme pathways in animal studies.
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